Option Care Health, Inc. (NASDAQ:OPCH) Insider Michael Bavaro Sells 30,996 Shares of Stock

Option Care Health, Inc. (NASDAQ:OPCH) insider Michael Bavaro sold 30,996 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Option Care Health Stock Performance

Shares of OPCH stock opened at $33.96 on Tuesday. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $34.57. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of 28.54, a PEG ratio of 2.30 and a beta of 1.35. The company has a 50-day simple moving average of $28.92 and a 200 day simple moving average of $28.07. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73.

Institutional Investors Weigh In On Option Care Health

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Option Care Health by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company’s stock worth $448,118,000 after purchasing an additional 75,313 shares during the period. Wellington Management Group LLP boosted its stake in Option Care Health by 84.6% in the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock valued at $425,143,000 after purchasing an additional 8,400,208 shares during the period. FMR LLC grew its holdings in Option Care Health by 134.0% in the 3rd quarter. FMR LLC now owns 7,516,448 shares of the company’s stock valued at $235,265,000 after buying an additional 4,304,896 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Option Care Health by 10.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock worth $203,204,000 after buying an additional 599,589 shares during the period. Finally, State Street Corp lifted its holdings in shares of Option Care Health by 1.4% during the third quarter. State Street Corp now owns 6,257,172 shares of the company’s stock worth $195,849,000 after buying an additional 83,395 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on OPCH. JPMorgan Chase & Co. increased their price objective on Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, January 24th. UBS Group assumed coverage on shares of Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company. Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $26.00 to $35.00 in a research note on Thursday, January 23rd. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $27.00 in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Option Care Health presently has an average rating of “Moderate Buy” and a consensus target price of $32.88.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.